{"entity":{"type":"insider","cik":"0001754937","url":"/insider/0001754937","json_url":"/insider/0001754937.json","name":"MOORE ALISON","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":11,"first":"2019-06-05","last":"2026-02-09","span_basis":"filed_date"},"name_variants":[{"name":"MOORE ALISON","source":"filing","n_filings":11,"first_seen":"2019-06-05","last_seen":"2026-02-09"}],"transactions":[{"id":5872126,"accession":"0001610717-26-000045","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-26-000045","line_url":"/filing/0001610717-26-000045#line-1","is_derivative":false,"issuer_cik":"0001200375","issuer_name":"CODEXIS, INC.","issuer_ticker":"CDXS","issuer_name_source":null,"issuer_url":"/issuer/0001200375","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3826.0,"shares_display":"3,826","price_per_share":1.3071,"price_display":"1.31","price_state":"stated","total_value":5000.9646,"total_display":"5,000.96","total_whole":"5,001","shares_owned_after":250506.0,"shares_owned_after_display":"250,506","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-06","filed_date":"2026-02-09","scope":"insider"},{"id":4928117,"accession":"0001610717-25-000363","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-25-000363","line_url":"/filing/0001610717-25-000363#line-1","is_derivative":false,"issuer_cik":"0001200375","issuer_name":"CODEXIS, INC.","issuer_ticker":"CDXS","issuer_name_source":null,"issuer_url":"/issuer/0001200375","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6239.0,"shares_display":"6,239","price_per_share":2.5051,"price_display":"2.51","price_state":"stated","total_value":15629.3189,"total_display":"15,629.32","total_whole":"15,629","shares_owned_after":169332.0,"shares_owned_after_display":"169,332","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-13","filed_date":"2025-10-15","scope":"insider"},{"id":6194175,"accession":"0001214659-22-004083","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001214659-22-004083","line_url":"/filing/0001214659-22-004083#line-1","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8698.0,"shares_display":"8,698","price_per_share":7.6326,"price_display":"7.63","price_state":"stated","total_value":66388.3548,"total_display":"66,388.35","total_whole":"66,388","shares_owned_after":120430.0,"shares_owned_after_display":"120,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-15","filed_date":"2022-03-17","scope":"insider"},{"id":4438350,"accession":"0001214659-21-003239","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001214659-21-003239","line_url":"/filing/0001214659-21-003239#line-1","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6164.0,"shares_display":"6,164","price_per_share":38.1391,"price_display":"38.14","price_state":"stated","total_value":235089.4124,"total_display":"235,089.41","total_whole":"235,089","shares_owned_after":102574.0,"shares_owned_after_display":"102,574","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-15","filed_date":"2021-03-17","scope":"insider"},{"id":2121633,"accession":"0001214659-20-008571","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001214659-20-008571","line_url":"/filing/0001214659-20-008571#line-4","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11031.0,"shares_display":"11,031","price_per_share":42.0,"price_display":"42.00","price_state":"stated","total_value":463302.0,"total_display":"463,302.00","total_whole":"463,302","shares_owned_after":108370.0,"shares_owned_after_display":"108,370","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-13","filed_date":"2020-10-13","scope":"insider"},{"id":2121629,"accession":"0001214659-20-008571","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001214659-20-008571","line_url":"/filing/0001214659-20-008571#line-2","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24233.0,"shares_display":"24,233","price_per_share":42.0,"price_display":"42.00","price_state":"stated","total_value":1017786.0,"total_display":"1,017,786.00","total_whole":"1,017,786","shares_owned_after":108370.0,"shares_owned_after_display":"108,370","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-12","filed_date":"2020-10-13","scope":"insider"},{"id":3097216,"accession":"0001214659-20-008532","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001214659-20-008532","line_url":"/filing/0001214659-20-008532#line-4","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39509.0,"shares_display":"39,509","price_per_share":41.0,"price_display":"41.00","price_state":"stated","total_value":1619869.0,"total_display":"1,619,869.00","total_whole":"1,619,869","shares_owned_after":108370.0,"shares_owned_after_display":"108,370","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-09","filed_date":"2020-10-09","scope":"insider"},{"id":3097207,"accession":"0001214659-20-008532","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001214659-20-008532","line_url":"/filing/0001214659-20-008532#line-2","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5065.0,"shares_display":"5,065","price_per_share":41.0,"price_display":"41.00","price_state":"stated","total_value":207665.0,"total_display":"207,665.00","total_whole":"207,665","shares_owned_after":117680.0,"shares_owned_after_display":"117,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-08","filed_date":"2020-10-09","scope":"insider"},{"id":3020946,"accession":"0001214659-20-008506","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001214659-20-008506","line_url":"/filing/0001214659-20-008506#line-2","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44574.0,"shares_display":"44,574","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":1782960.0,"total_display":"1,782,960.00","total_whole":"1,782,960","shares_owned_after":117680.0,"shares_owned_after_display":"117,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-06","filed_date":"2020-10-08","scope":"insider"},{"id":2914722,"accession":"0001214659-20-002736","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001214659-20-002736","line_url":"/filing/0001214659-20-002736#line-1","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":19.1947,"price_display":"19.19","price_state":"stated","total_value":71980.125,"total_display":"71,980.12","total_whole":"71,980","shares_owned_after":63021.0,"shares_owned_after_display":"63,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-16","filed_date":"2020-03-18","scope":"insider"},{"id":8214608,"accession":"0001214659-19-005941","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001214659-19-005941","line_url":"/filing/0001214659-19-005941#line-6","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21067.0,"shares_display":"21,067","price_per_share":32.1295,"price_display":"32.13","price_state":"stated","total_value":676872.1765,"total_display":"676,872.18","total_whole":"676,872","shares_owned_after":66067.0,"shares_owned_after_display":"66,067","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-18","filed_date":"2019-09-18","scope":"insider"},{"id":8214596,"accession":"0001214659-19-005941","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001214659-19-005941","line_url":"/filing/0001214659-19-005941#line-4","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22503.0,"shares_display":"22,503","price_per_share":32.1095,"price_display":"32.11","price_state":"stated","total_value":722560.0785,"total_display":"722,560.08","total_whole":"722,560","shares_owned_after":66067.0,"shares_owned_after_display":"66,067","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-17","filed_date":"2019-09-18","scope":"insider"},{"id":8214589,"accession":"0001214659-19-005941","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001214659-19-005941","line_url":"/filing/0001214659-19-005941#line-2","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5257.0,"shares_display":"5,257","price_per_share":32.0019,"price_display":"32.00","price_state":"stated","total_value":168233.9883,"total_display":"168,233.99","total_whole":"168,234","shares_owned_after":66067.0,"shares_owned_after_display":"66,067","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-16","filed_date":"2019-09-18","scope":"insider"},{"id":7789703,"accession":"0001209191-19-043755","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-19-043755","line_url":"/filing/0001209191-19-043755#line-6","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11819.0,"shares_display":"11,819","price_per_share":29.845,"price_display":"29.84","price_state":"stated","total_value":352738.055,"total_display":"352,738.06","total_whole":"352,738","shares_owned_after":65373.0,"shares_owned_after_display":"65,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-30","filed_date":"2019-07-30","scope":"insider"},{"id":7789700,"accession":"0001209191-19-043755","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-043755","line_url":"/filing/0001209191-19-043755#line-4","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23815.0,"shares_display":"23,815","price_per_share":29.3878,"price_display":"29.39","price_state":"stated","total_value":699870.457,"total_display":"699,870.46","total_whole":"699,870","shares_owned_after":65373.0,"shares_owned_after_display":"65,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-29","filed_date":"2019-07-30","scope":"insider"},{"id":7789696,"accession":"0001209191-19-043755","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-043755","line_url":"/filing/0001209191-19-043755#line-2","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13193.0,"shares_display":"13,193","price_per_share":29.1817,"price_display":"29.18","price_state":"stated","total_value":384994.1681,"total_display":"384,994.17","total_whole":"384,994","shares_owned_after":65373.0,"shares_owned_after_display":"65,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-26","filed_date":"2019-07-30","scope":"insider"},{"id":7805321,"accession":"0001209191-19-034861","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-034861","line_url":"/filing/0001209191-19-034861","is_derivative":false,"issuer_cik":"0001737287","issuer_name":"Allogene Therapeutics, Inc.","issuer_ticker":"ALLO","issuer_name_source":null,"issuer_url":"/issuer/0001737287","owner_cik":"0001754937","owner_name":"MOORE ALISON","owner_display_name":"MOORE ALISON","owner_url":"/insider/0001754937","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48828.0,"shares_display":"48,828","price_per_share":26.76280697960187,"price_display":"26.76","price_state":"stated","total_value":1306774.3392,"total_display":"1,306,774.34","total_whole":"1,306,774","shares_owned_after":39180.0,"shares_owned_after_display":"39,180","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-03","filed_date":"2019-06-05","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001200375","name":"CODEXIS, INC.","url":"/issuer/0001200375","role":"Director, Officer (President and CEO)","n_filings":2,"first_seen":"2025-10-15","last_seen":"2026-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001737287","name":"Allogene Therapeutics, Inc.","url":"/issuer/0001737287","role":"Officer (Chief Technical Officer)","n_filings":9,"first_seen":"2019-06-05","last_seen":"2022-03-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001754937","retrieved_at":"2026-08-25T03:11:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}